Introduction: Symptomatic urinary tract infection is a known complication of cystoscopy with ureteral stent removal. However, little is known about the incidence and risk factors for urinary tract infection after cystoscopy in renal transplant recipients, who likely represent a high risk cohort. In this study we determined the infection rate after cystoscopy with stent removal in this population and identified opportunities for care improvement.
Cystoscopy for ureteral stent removal after renal transplantation is a common reason for urology referral. Stent placement after renal transplantation serves to decrease the occurrence of post-transplant urological complications such as ureteral anastomotic leak and obstruction. 1, 2 The transplant stent is typically removed by a urologist 4 to 6 weeks after transplantation. Urinary tract infection is common after renal transplantation and evidence is conflicting regarding whether ureteral stent placement/removal further contributes to an increased incidence of bacteriuria or UTI. 3, 4 Due to the presence of comorbidities, recent GU manipulation and the use of immunosuppressive medications to prevent organ rejection, renal transplant recipients are likely predisposed to the development of infections and are commonly prescribed daily antibiotic prophylaxis. 5 In the general population cystoscopy is well tolerated. However, UTI is a known posttreatment complication. Studies report asymptomatic bacteriuria occurring in 5% to 25% of patients and symptomatic infection occurring in approximately 5% of patients. 6e9 Guidelines from the AUA (American Urological Association) and the ASHP (American Society of Health-System Pharmacists) recommend antibiotic administration before cystoscopy in patients at increased risk for infection (eg advanced age, abnormal urinary tract, indwelling tubes, use of immunosuppression) and those undergoing GU tract manipulation (see Appendix). 10, 11 Nonetheless, the benefits of prophylaxis must always be balanced with the risks of antibiotic complications and resistance. 12 To our knowledge prior studies have not examined the rate of infection after cystoscopy and stent removal when performed in renal transplant recipients. We performed a retrospective cohort study to determine the rate of symptomatic UTI in transplant recipients undergoing cystoscopic stent removal and the influence of antibiotic prophylaxis in this population.
Methods

Clinic Protocol
Between April 2012 and May 2014, 5,488 outpatient cystoscopies were performed at the 2 outpatient urology clinics at our institution. Our cohort included all renal transplant recipients who underwent outpatient cystoscopy with stent removal based on CPT and ICD-9 codes. All flexible cystoscopies were performed after genitalia were prepped with povidone-iodine solution. In addition, 2% lidocaine jelly was instilled into the urethra before the procedure. Ureteral stent removal was performed by an attending urologist using a flexible grasper (no stent had an attached string).
After each procedure the cystoscopes were cleaned using an enzymatic cleanser (V. MuellerÒ), sterile water wash and chemical sterilization with peracetic acid (Steris S40Ò). After the procedure the patients were given an informational handout and were instructed to notify the clinic if they developed a temperature of 101F or greater. Neither clinic had a formalized protocol regarding the use of prophylactic antibiotics before the procedure and the administration of antibiotic prophylaxis was left to clinician preference. Patients were uniformly on prophylactic dose antibiotics (trimethoprim/sulfamethoxazole or dapsone) before stent removal.
Study Design
After institutional review board approval was obtained, a retrospective review of medical records was performed and data were collected from electronic medical records. The data collected included patient characteristics (age, race, diabetes, smoking history, prednisone use, deceased or living donor) and post-transplant outcomes as defined by patients' nephrologist (time to stent removal, hospital readmission, nongenitourinary tract infection, delayed graft function, acute cellular rejection, major urological complication [urine leak]). Cases were defined as meeting the criteria for symptomatic UTI within 30 days after cystoscopy. Using prior literature, CDC (Centers for Disease Control and Prevention) surveillance definitions and discussions with the hospital epidemiologist (TRT), we developed criteria to define patients with symptomatic UTI. 13, 14 These included 1) one of the signs or symptoms of fever, urgency, frequency, dysuria, prostate tenderness or suprapubic tenderness with no other recognized cause, AND positive urine culture (10 5 microorganisms or more) with no more than 2 species present, OR 2) 2 of the previously mentioned signs and symptoms with no other recognized cause, AND at least 1 of a) positive dipstick for leukocyte esterase and/or nitrate, b) pyuria (urine specimen with more than 10 white blood cells per mm 3 ), c) organisms seen on Gram stain of unspun urine, d) at least 2 urine cultures with repeated isolation of the same uropathogen (gram-negative bacteria or Staphylococcus saprophyticus) with 10 2 colonies per ml or more in nonvoided specimens, e) less than 10 5 colonies per ml of a single uropathogen in a patient being treated with an effective antimicrobial agent for UTI, f) physician diagnosis of UTI or prostatitis, or g) physician initiation of appropriate therapy for UTI or prostatitis. Student's t-test and Fisher's exact test were used to evaluate patient characteristics and transplant outcomes associated with symptomatic UTI. Chi-squared tests were 2-sided and all tests with p <0.05 were considered significant. Statistics were completed using STATAÒ Release 13.1.
As a secondary outcome we investigated whether the use of prophylactic antibiotics, in addition to daily prophylaxis taken by all transplant recipients at our institution for the prevention of infectious diseases, was associated with symptomatic UTI after cystoscopy.
Prior studies indicate that patients undergoing cystoscopy at our institution receive prophylactic antibiotics approximately 75% of the time. 15 With a study cohort of approximately 320 transplant recipients, we calculated that we had greater than 80% power to detect a difference in symptomatic UTI of 2% in those who received antibiotics vs 10% in those who did not, with a 0.05 type I error probability. Given that transplant recipients are already on a daily antibiotic and may receive less prophylactic dosing, we calculate that power approaches 98% if half of the cohort receives prophylactic antibiotics.
Results
A total of 324 renal transplant recipients underwent cystoscopy with stent removal during the study period. Patient characteristics are shown in table 1. Average patient age was 50 years. Overall 42.3% of patients were female and 70.4% were white. Stents were removed an average of 28.6 days (SD 6.9) after transplantation and timing was left to the discretion of the referring transplant team. All patients were taking trimethoprim/sulfamethoxazole or dapsone as prophylactic antibiotics. An additional 165 (52.5%) patients received a dose of prophylactic antibiotic before cystoscopy to remove ureteral stents. Of these 165 patients 163 (98.8%) received a fluoroquinolone as prophylaxis before the procedure. No adverse events related to antibiotic use were noted in patients who received a prophylactic fluoroquinolone. There were 9 patients (2.8%) who met the criteria for symptomatic UTI within 30 days after cystoscopy. Of the 9 symptomatic UTIs 8 had a positive urine culture, of which the involved bacteria were Escherichia coli (3), Klebsiella pneumoniae (2), Citrobacter (2 different species) and Enterococcus faecalis (1). The patient with culture negative urine had a UTI diagnosed by a physician due to frequency, incomplete emptying and prostatic tenderness. Of the 8 bacterial isolates 3 (37.5%) were resistant to fluoroquinolones. Of the 9 patients with UTI 2 required hospital admission for the treatment of pyelonephritis. None required intensive care unit admission. Overall in the cohort 21 patients (6.5%) had asymptomatic bacteriuria. Table 2 shows patient characteristics as well as posttransplant measures and their association with symptomatic UTI. Female sex was associated with symptomatic UTI (p¼0.04). However, no other patient or transplant related factors were associated with UTI and the lack of prednisone as an immunosuppressive agent trended toward an association with symptomatic UTI (p¼0.10). Notably, the lack of prophylactic antibiotic use before cystoscopy with stent removal was not associated with symptomatic UTI (p¼0.32, see figure) .
Discussion
In this cohort of renal transplant recipients undergoing cystoscopic ureteral stent removal we found a 2.8% rate of symptomatic UTI. Thus, despite multiple factors that may place this group at increased risk for UTI, including the presence of comorbidities, use of immunosuppressive medications and recent surgical intervention, 13 the risk of UTI after stent removal in renal transplant recipients may not be different from that found in the general population. The low rate of symptomatic UTI seen in our cohort differs from that in many studies examining infections in the post-transplant population. While the majority of these studies evaluate patients for at least 3 months after transplantation (as opposed to 1 month after stent removal in our cohort), the rates of infection are strikingly different. Large studies examining only acute graft pyelonephritis (fever, positive urine culture and urinary symptoms) have shown rates of infection at 13% to 16.5%. 16, 17 This contrasts with the 2 patients out of 324 (0.6%) who had acute pyelonephritis in our study, albeit with an admittedly shorter observation time. In terms of cystitis, 3 retrospective cohorts of more than 100 patients each demonstrated UTI rates of 34.5%, 18 44.8% 19 and 33.7%. 20 Importantly, these studies included patients with asymptomatic positive urine culture results in their definition of UTI, representing much less stringent criteria. While some believe that asymptomatic bacteriuria is a reasonable outcome in a transplant population given a possible association with graft related complications, 21 evidence is lacking as to whether intervention for asymptomatic bacteriuria has any effect on transplant related outcomes. Furthermore, the effect of daily low dose prophylactic antibiotics on bacteriuria was not established at the time of these studies, as evidenced by the 6.5% rate of asymptomatic bacteriuria seen in our population, among which all patients received daily prophylaxis. Multiple randomized prospective studies investigating outpatient flexible cystoscopy have demonstrated low rates of UTI in patients randomized to placebo administration before the procedure. While the definition of UTI varied, recent large studies demonstrated symptomatic UTI rates of 3%, 22 2.5% 23 and 0.8%. 24 Notably, patients in these studies did not undergo cystoscopy with urinary tract manipulation such as stent removal. Guidelines place patients at increased risk for infection when manipulation occurs, even though evidence supporting this practice has largely been extrapolated from studies investigating the efficacy of prophylactic antibiotic use before transurethral resection of the prostate. 10 A number of prior studies, while limited by the previously mentioned broad definition of UTI, have investigated risk factors associated with infection in patients after renal Figure. Effect of full dose antibiotic prophylaxis before cystoscopy on symptomatic UTI. Medical records of renal transplant recipients who underwent cystoscopy for stent removal were examined for antibiotic administration before cystoscopy and symptomatic UTI criteria 30 days after cystoscopy. Patients who met criteria for UTI are represented in gray and those who did not meet criteria for UTI are represented in white. Patients who did vs did not receive treatment dose prophylaxis before cystoscopy in addition to universally administered daily prophylaxis are shown in upper and lower bars, respectively.
transplantation. A retrospective analysis by Camargo et al demonstrated that older age, acute rejection and deceased donor transplantation were associated with UTI (definition unknown, although it likely included bacteriuria given a 33.7% rate of infection). 20 A separate cohort showed that immunosuppressive regimen, deceased donor transplantation, duration of bladder catheterization and length of hospital stay were associated with symptomatic UTI or bacteriuria. 19 In our contemporary cohort female sex was associated with symptomatic UTI (p¼0.04). This finding is likely valid as female sex is a known risk factor for UTI and is mechanistically plausible given the short female urethral length. 14 Further studies are needed, particularly to determine if antibiotics may be safely omitted in select renal transplant recipients. Antibiotics implicitly risk complications such as gastrointestinal distress, opportunistic infections and drug reactions. 25 These potential downsides, as well as increasing rates of antimicrobial resistance, 14, 26 have contributed to an increase in awareness of the need for urologists to practice antibiotic stewardship. 27 Furthermore, a recent study advocates for consideration of prophylactic antibiotic omission in patients undergoing outpatient cystoscopy, including those at increased risk for infection. 6 While infectious disease 11 and urology 10 guidelines do not recommend such an approach, in a recent study our group demonstrated that more narrow criteria may be safely used to risk stratify patients undergoing outpatient cystoscopy, especially given the high rates of resistance to recommended prophylactics. 15 Interestingly, treatment dose antibiotic prophylaxis was not associated with UTI in this cohort, a group with multiple risk factors for UTI as defined by the previously mentioned guidelines, including immune suppression, recent hospitalization and GU tract manipulation. Given this finding it may be reasonable to advocate for decreased peri-procedural antibiotic use in this population, especially given the broad use of daily antibiotic prophylaxis in this group. However, a difference in absolute rates of symptomatic UTI was demonstrated in our cohort, with 3.9% of patients in whom prophylaxis was omitted having a symptomatic UTI compared to 1.8% of those who received medication before the procedure. These rates of UTI are actually lower than those expected at the onset of the study. A post hoc power calculation reveals that 640 patients would have been needed to detect a significant difference given the rates of infection and pre-procedural antibiotic use in our cohort. Therefore, our study was limited in sample size and the finding that antibiotic prophylaxis is not associated with symptomatic UTI may reflect a type II error. Other limitations of our study, including potential bias related to its retrospective nature, which may have limited the number of identified UTIs, make it difficult to definitively conclude that peri-procedural antibiotics do not prevent symptomatic UTI in this population. Additionally, urine cultures done before the procedure were not uniformly available to guide prophylaxis. Given the potential consequences of a severe urinary tract infection in this population, including complications related to graft health or immune suppression, we do not recommend cessation of prophylactic antibiotic dosing in this group until larger, prospective studies have been completed.
To our knowledge, this is the first study to determine the rate of symptomatic UTI after post-transplant outpatient cystoscopy and stent pull. The infection rate of 2.8% is comparable to rates of symptomatic UTI after cystoscopy in the general population, suggesting that the UTI risk in this group may be lower than previously expected. In addition, we identified sex as a factor associated with symptomatic UTI after stent removal. While the efficacy of full dose prophylactic antibiotics in the prevention of post-procedural UTI remains to be proven, transplant recipients represent an at risk population for whom preprocedural antibiotic prophylaxis should likely continue. Further prospective studies (ideally in the setting of a randomized clinical trial) are needed to determine the patients at greatest risk for symptomatic UTI after renal transplantation. removal the results of pre-procedural urinalyses and urine cultures are usually available, as are patient medication lists. If no UTI is present, no additional antibiotic prophylaxis is necessary. If a UTI is present an antibiotic can be chosen on the basis of sensitivity results, administered at the time of stent removal and continued for a course of treatment.
Appendix
Are patients on prophylactic antibiotics harmed by a single dose of another antibiotic at the time of stent removal? Probably not.
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